Skip to main content
. Author manuscript; available in PMC: 2018 Feb 1.
Published in final edited form as: Cancer Res. 2016 Nov 29;77(3):766–779. doi: 10.1158/0008-5472.CAN-16-1346

Figure 7. CNOT3 overexpression is associated with advanced CRC and high risk of relapse.

Figure 7

(A) IHC for CNOT3 in representative CRC specimens with typical (<1% to 5% of stained cells) or high (>5% to 20% of stained cells) CNOT3+ cell fractions. Scale bar, 50 µm. (B) Association of high CNOT3+ cell fractions with increasing CRC stage. (C) Kaplan-Meier survival analysis of patients with CRC stages II and III (combined, left, N=307) or stage II only (right, N=237), showing reduced long-term disease-free survival in cases with excess CNOT3. (D) Multivariate analysis in stages II and III (combined) or in stage II CRC of the influence of various factors, including high CNOT3+ cell fraction, on patient survival. (E) Kaplan-Meier survival analysis of patients whose CRCs did (red) or did not (blue) overexpress TRIM28. (F) Kaplan-Meier survival analysis of 296 patients with microsatellite-stable (MSI-negative) tumors with low or high CNOT3 mRNA levels in CRC stages II and III from The Cancer Genome Atlas collection.